Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MAPK4
REST API REST API
Homo sapiens
MAPK4 is differentially expressed in 106 experiments: 61 organism parts: liver, caudate nucleus, ... (59 more);, 91 disease states: normal, healthy, ... (89 more);, 22 cell types 82 cell lines 10 compound treatments and 51 other conditions.
Synonyms PRKM4, Erk3-related, Erk4
Orthologs FUS3 (Saccharomyces cerevisiae)   KSS1 (Saccharomyces cerevisiae)   MAPK4 (Bos taurus)   Q4H3L4_CIOIN (Ciona intestinalis)   mapk4 (Danio rerio)   Mapk4 (Mus musculus)   Mapk4 (Rattus norvegicus)   mapk4 (Xenopus laevis)   MAPK4 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein tyrosine kinase activity, MAP kinase activity, ATP binding, cell cycle, nucleotide binding, protein serine/threonine kinase activity, protein kinase activity, protein phosphorylation
InterPro Term Prot_kinase_cat_dom, Erk_3_4_MAPK, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession Q0VG04, P31152, B4E104, B4DEW2
Search EB-eye ENSG00000141639
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MTAB-24, E-MTAB-25, ... (15 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-22639, E-GEOD-2450, E-GEOD-24147, E-GEOD-19480, ... (15 experiments)

Factor Value U/D Experiments
MCF-10A
2
E-TABM-420, E-GEOD-14990
MCF-7
2
E-GEOD-20081, E-GEOD-3529
cultured
1
E-MTAB-62
CaOv3
1
E-MTAB-37
CEMC1
1
E-MTAB-37
NCIH1437
1
E-MTAB-37
76 more value(s).


Cell type

studied in E-AFMX-5, E-GEOD-18811, E-GEOD-19069, E-MTAB-24, E-MTAB-25, ... (17 experiments)

Factor Value U/D Experiments
plasma cell
2
E-GEOD-6691, E-MEXP-2360
vascular smooth muscle cell
1
E-TABM-130
chondrocyte
1
E-TABM-130
1
1
E-TABM-145
neutrophil
1
E-GEOD-12662
immortalized cell culture
1
E-GEOD-14990
16 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-1869, E-GEOD-3365, E-MEXP-2069, ... (18 experiments)

Factor Value U/D Experiments
normal
5
E-GEOD-3365, E-GEOD-9692, E-GEOD-12662, E-MEXP-2069, E-GEOD-7307 ... (5 experiments)
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
prior to onset of multiple sclerosis
1
E-GEOD-14895
teratozoospermia
1
E-GEOD-6872
B-cell lymphoma
1
E-MTAB-62
tumor
1
E-GEOD-19188
85 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-3284, E-GEOD-5824, E-GEOD-995, E-MEXP-1958, ... (6 experiments)

Factor Value U/D Experiments
none
72
2
E-GEOD-5824, E-MEXP-1958
lipopolysaccharide
7
1
E-MEXP-1958
rapamycin
1
E-GEOD-5824
bacterial endotoxin
1
1
E-GEOD-3284
trichostatin A
1
E-MEXP-1269
phorbol 12-myristate 13-acetate
1
E-GEOD-995
4 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-16363

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-108

Genotype
studied in E-GEOD-22056, E-MEXP-421

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-GEOD-19330, E-TABM-666, ... (16 experiments)

Infection
studied in E-GEOD-12254, E-MEXP-561

Ki67 ihc
studied in E-GEOD-21653

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455, E-MEXP-958

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-1657

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-19246, E-GEOD-1343

RNAi
studied in E-MEXP-101, E-MEXP-2759

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

Subtype
studied in E-GEOD-24283

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-19246, E-GEOD-13818

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 1.075 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM